Bucillamine mechanism inhibiting IL-1β-induced VEGF production from fibroblast-like synoviocytes

International Immunopharmacology

Volumn 7, Issue 12, 2007, Pages 1569-1576

  Tsuji, Fumio ^a,b   Seki, Iwao ^a   Aono, Hiroyuki ^a,c   Odani, Noriko ^a   Mizutani, Keiko ^a   Okamoto, Masahiro ^a   Sasano, Minoru ^a  

^a SANTEN PHARMACEUTICAL CO LTD   (Japan)

^b GIFU UNIVERSITY   (Japan)

^c NARA INSTITUTE OF SCIENCE AND TECHNOLOGY   (Japan)

Author keywords

Bucillamine; HIF 1; IL 1; Sinoviocyte; Sp1; VEGF

Indexed keywords

4,5,6,7 TETRAHYDRO 7,7 DIMETHYL 6 OXO 3H 1,2,5 DITHIAZEPINE 4 CARBOXYLIC ACID; BUCILLAMINE; DRUG METABOLITE; HYPOXIA INDUCIBLE FACTOR 1; I KAPPA B ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN C JUN; PROTEIN KINASE B; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FIBROBLAST; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SYNOVIOCYTE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; CELL LINE; CYSTEINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; I-KAPPA B PROTEINS; INTERLEUKIN-1BETA; INTERLEUKIN-6; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-JUN; SP1 TRANSCRIPTION FACTOR; SYNOVIAL MEMBRANE; TRANSCRIPTION FACTOR AP-1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34848894923     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2007.07.020     Document Type: Article

References (40)

1. Harris Jr. E.D. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 322 (1990) 1277-1289
2. Buchan A.B., Barrett K., Fujita T., Taniguchi T., Maini R., and Feldmann M. Detection of activated T cell products in the rheumatoid joint using cDNA probes to interleukin-2 (IL-2), IL-2 receptor and IFN-γ. Clin Exp Immunol 71 (1988) 295-301
3. Arend W.P., and Dayer J.M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 38 (1995) 151-160
4. Firestein G.S., Alvaro-Garcia J.M., and Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 144 (1990) 3347-3353
5. 2 enhances interleukin 8 (IL-8) and IL-6 but inhibits GMCSF production by IL-1 stimulated human synovial fibroblasts in vitro. J Rheumatol 23 (1996) 862-868
6. Jackson J.R., Minton J.A.L., Ho M.L., Wei N., and Winkler J.D. Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1β. J Rheumatol 24 (1997) 1253-1259
7. Sone H., Kawakami Y., Sakauchi M., Nakamura Y., Takahashi A., Shimano H., et al. Neutralization of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice. Biochem Biophys Res Commun 281 (2001) 562-568
8. Grosios K., Wood J., Esser R., Raychaudhuri A., and Dawson J. Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis. Inflamm Res 53 (2004) 133-142
9. Tsuji F., Aono H., Okamoto M., and Sasano M. Bucillamine, a unique anti-rheumatic drug. Curr Top Pharmacol 10 (2006) 43-46
10. Iwatami M., Inoue E., Nakamura T., Nakajima A., Hara M., Tomatsu T., et al. Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA. Mod Rheumatol 16 (2006) 376-380
11. Horwitz L.D. Bucillamine: a potent thiol donor with multiple clinical applications. Cardiovasc Drug Rev 21 (2003) 77-90
12. Nagashima M., Yoshino S., Aono H., Takai M., and Sasano M. Inhibitory effects of anti-rheumatic drugs on vascular endothelial growth factor in cultured rheumatoid synovial cells. Clin Exp Immunol 116 (1999) 360-365
13. Tsuji F., Matsuoka H., Aono H., Takai M., Horiuchi M., Nishimura K., et al. Effects of sulfhydryl compounds on interleukin-1-induced vascular endothelial growth factor production in human synovial stromal cells. Biol Pharm Bull 23 (2000) 663-665
14. Koyama S., Takagi H., Otani A., Oh H., Nishimura K., and Honda Y. Inhibitory mechanism of vascular endothelial growth factor (VEGF) by bucillamine. Br J Pharmacol 137 (2002) 901-909
15. Matsuno H., Sugiyama E., Muraguchi A., Nezuka T., Kubo T., Matsuura K., et al. Pharmacological effects of SA96 (bucillamine) and its metabolites as immunomodulating drugs-the disulfide structure of SA96 metabolites plays a critical role in the pharmacological action of the drug. Int J Immunopharmacol 20 (1998) 295-304
16. Hirohata S., and Lipsky P.E. Regulation of B cell function by bucillamine, a novel disease-modifying antirheumatic drug. Clin Immunol Immunopathol 66 (1993) 43-51
17. Tischer E., Mitchell R., Hartman T., Silva M., Gospodarowicz D., Fiddes J.C., et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266 (1991) 11947-11954
18. Wang G.L., Jiang B.H., and Semenza G.L. Effect of altered redox states on expression and DNA-binding activity of hypoxia-inducible factor 1. Biochem Biophys Res Commun 212 (1995) 550-556
19. Aono H., Hasunuma T., Fujisawa K., Nakashima T., Yamamoto K., Mita S., et al. Direct suppression of human synovial cell proliferation in vitro by salazosulfapyridine and bucillamine. J Rheumatol 22 (1995) 65-70
20. Granet C., Maslinski W., and Miossec P. Increased AP-1 and NF-κB activation and recruitment with the combination of the proinflammatory cytokines IL-1β, tumor necrosis factor alpha and IL-17 in rheumatoid synoviocytes. Arthritis Res Ther 6 (2004) R190-R198
21. Jung Y.J., Isaacs J.S., Sunmin L., Trepel J., and Neckers L. IL-1β-mediated up-regulation of HIF-1α via an NFκB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 17 (2003) 2115-2117
22. Treins C., Giorgetti-Peraldi S., Murdaca J., Semenza G.L., and Van Obberghen E. Insulin stimulates hypoxia-inducible factor-1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 277 (2002) 27975-27981
23. Jiang B.H., Zheng J.Z., Aoki M., and Vogt P.K. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci U S A 97 (2000) 1749-1753
24. Sandau K.B., Zhou J., Kietzmann T., and Brune B. Regulation of the hypoxia-inducible factor-1α by the inflammatory mediators nitric oxide and tumor necrosis factor-α in contrast to desferroxamine and phenylarsine oxide. J Biol Chem 276 (2001) 39805-39811
25. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.M., et al. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60 (2000) 1541-1545
26. Laughner E., Taghavi P., Chiles K., Mahon P.C., and Semenza G.L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor-1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21 (2001) 3995-4004
27. Hellwig-Bürgel T., Stiehl D.P., Wagner A.E., Metzen E., and Jelkmann W. Hypoxia-inducible factor-1 (HIF-1): a novel transcription factor in immune reactions. J Interferon Cytokine Res 25 (2005) 297-310
28. Hur E., Chang K.Y., Lee E., Lee S.K., and Park H. Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxia-inducible factor-1α. Mol Pharmacol 59 (2001) 1216-1224
29. Safe S., and Abdelrahim M. Sp transcription factor family and its role in cancer. Eur J Cancer 41 (2005) 2438-2448
30. Tanaka T., Kanai H., Sekiguchi K., Aihara Y., Yokoyama T., Arai M., et al. Induction of VEGF gene transcription by IL-1β is mediated through stress-activated MAP kinases and Sp1 sites in cardiac myocytes. J Mol Cell Cardiol 32 (2000) 1955-1967
31. Pore N., Liu S., Shu H.K., Li B., Haas-Kogan D., Stokoe D., et al. Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. Mol Biol Cell 15 (2004) 4841-4853
32. Ryuto M., Ono M., Izumi H., Yoshida S., Weich H.A., Kohno K., et al. Induction of vascular endothelial growth factor by tumor necrosis factor a in human glioma cells: possible roles of SP-1. J Biol Chem 271 (1996) 28220-28228
33. Shiller M., Böhm M., Dennler S., Ehrchen J.M., and Mauvial A. Mitogen-and stress-activated protein kinase 1 is critical for interleukin-1-induced, CREB-mediated, c-fos gene expression in keratinocytes. Oncogene 25 (2006) 4449-4457
34. Georganas C., Liu H., Perlman H., Hoffmann A., Thimmapaya B., and Pope R.M. Regulation of IL-6 and IL-8 expression in rheumatoid arthritis synovial fibroblasts: the dominant role for NF-κB but not C/EBPβ or c-Jun. J Immunol 165 (2000) 7199-7206
35. Hayashi M., Matsunaga K., Okahara A., and Mita S. Effect of bucillamine (SA96) on type II collagen induced arthritis in rats. J Rheumatol 18 (1991) 691-695
36. Tsuji F., Miyake Y., Aono H., Kawashima Y., and Mita S. Effects of bucillamine and N-acetyl-L-cysteine on cytokine production and collagen-induced arthritis (CIA). Clin Exp Immunol 115 (1999) 26-31
37. Hikichi T., Mori F., Sasaki M., Takamiya A., Nakamura M., Shishido N., et al. Inhibitory effect of bucilamine on laser-induced choroidal neovascularization in rats. Curr Eye Res 24 (2002) 1-5
38. Yanagi Y., Tamaki Y., Obata R., Muranaka K., Homma N., Matsuoka H., et al. Subconjunctival administration of bucillamine suppresses choroidal neovascularization in rat. Invest Ophthalmol Vis Sci 43 (2002) 3495-3499
39. Ichikawa Y., Saito T., Yamanaka H., Akizuki M., Kondo H., Kobayashi S., et al. Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study. Mod Rheumatol 15 (2005) 323-328
40. Fiehn C., Wunder A., Krienke S., Max R., Ho A.D., and Moehler T. Lack of evidence for inhibition of angiogenesis as a central mechanism of the antiarthritic effect of methotrexate. Rheumatol Int 25 (2005) 108-113